Dear Friends of LRF, Since its inception, one of the Lymphoma Research Foundation’s (LRF) guiding priorities has been pushing the field of lymphoma/chronic lymphocytic leukemia (CLL) forward toward a future free of the disease. It’s why we have funded over…
Where Are They Now? Martin Rivas, PhD When did you become interested in the study of biology? In oncology and lymphoma specifically? I was attracted to nature from a very young age. I was curious about all animals, but whales…
Following a Passion to Improve Patients’ Lives Lindsay M. Morton, PhD, Director of the Radiation Epidemiology Branch and head of the Cancer Survivorship Research Unit in the Division of Cancer Epidemiology and Genetics (DCEG) at the National Cancer Institute (NCI),…
Story of Hope: Scott Fink Scott Fink is a born-and-bred New Yorker, married 20 years to his wife, Kelly, and father to 14-year-old twin daughters. He’s called New York City home for most of his life, aside from his undergraduate…
On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved epcoritamab-bysp (Epkinly, co-developed by Genmab and AbbVie) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. “The…
Lymphoma Research Foundation Awards More Than $5.4 Million in Lymphoma Research Grants New York, NY (May 1, 2023) – The Lymphoma Research Foundation (LRF), the nation’s largest nonprofit organization devoted to funding innovative lymphoma research and serving the lymphoma community,…
On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL),…
On April 6, 2023, AbbVie announced its intent to withdraw the accelerated approval of ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who…
